Dr. McGregor on Whether Patients Need Frontline Combinations in RCC

Video

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Frontline combination therapies have taken hold of the RCC landscape, but physicians have yet to determine whether everyone should receive a frontline combination therapy, says McGregor. In the CheckMate-214 trial, the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) was compared with sunitinib (Sutent) in the frontline setting and showed an improvement in overall survival. However, patients with good-risk disease demonstrated a higher rate of progression-free survival with sunitinib than with the combination.

Additionally, patients in the trial were accrued prior to the FDA’s approval of the combination in the United States. Less than 30% of patients who received sunitinib crossed over to receive immunotherapy in the trial. Researchers did not allow crossover until the data were reported, which was in 2016. Therefore, it is unknown if patients who receive frontline sunitinib and second-line immunotherapy experience the same magnitude of benefit, explains McGregor.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.